Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
131.3 USD | +0.44% | +4.47% | +20.53% |
05:51pm | Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 | MT |
05:05pm | Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.53% | 331B | |
+26.13% | 653B | |
+27.00% | 556B | |
-6.56% | 354B | |
+3.13% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.20% | 144B | |
-11.74% | 143B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck's Phase 2b Study of MK-0616 Showed Significant Reduction of Bad Cholesterol in Adults With Hypercholesterolemia